BIOGEN INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $BIIB in the last 30 days.
See all $BIIB insider activity →Biogen Inc. (BIIB) stock reached a 52-week high of 225.88 USD, up 61.6% over the past year. The company's market cap is $33.26 billion, with a P/E ratio of 39.41. Analysts raised price targets, citing potential in its lupus drug and other pipeline developments. InvestingPro suggests the stock is undervalued.
AbbVie (NYSE:ABBV) reported Q2 revenue of $16.99B, up 10.2% YoY, beating estimates by 1.2%. Biogen (NASDAQ:BIIB) saw revenue rise 3.4% YoY, exceeding expectations by 12.1%. Myriad Genetics (NASDAQ:MYGN) reported a 10.5% YoY revenue decline, missing estimates by 8.2%. Gilead Sciences (NASDAQ:GILD) reported $7.80B in revenue, up 10.2% YoY, beating estimates by 6.2%. Moderna (NASDAQ:MRNA) reported $145M in revenue, up 2.1% YoY, surpassing expectations by 35.8%.
Biogen Inc's (BIIB) stock fell 7% after presenting mixed mid-stage trial results for its Alzheimer's drug diranersen. The study showed positive signals, particularly for the 60 mg dose, but raised questions about dosing and consistency. RBC questioned the replicability of results, while Stifel maintained a 'Buy' rating. BIIB has a 12-month average price target of $224.45, up 7% from the last close.
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning BIIB (BIOGEN INC.). Coverage has skewed bullish: 2 bullish, 1 neutral, and 1 bearish.
Recent BIIB coverage spans regulation, technology and market movers.
Price target upgrades suggest upside potential but no immediate catalyst.
Positive earnings surprise drives short‑term rally.
The mixed trial results raise doubts about dosing and commercial potential, likely prompting short‑term selling pressure.
Potential revenue boost for Biogen in Ireland and possible EU-level pricing discussions.
Positive regulatory approval may boost Biogen's sales outlook and share price.
AlphAI scores every news story that mentions BIIB with an AI model for sentiment and relevance, and aggregates insider trades from BIOGEN INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Biogen Inc. (BIIB) stock reached a 52-week high of 225.88 USD, up 61.6% over the past year. The company's market cap is $33.26 billion, with a P/E ratio of 39.41. Analysts raised price targets, citing potential in its lupus drug and other pipeline developments. InvestingPro suggests the stock is undervalued.
1 min readAbbVie (NYSE:ABBV) reported Q2 revenue of $16.99B, up 10.2% YoY, beating estimates by 1.2%. Biogen (NASDAQ:BIIB) saw revenue rise 3.4% YoY, exceeding expectations by 12.1%. Myriad Genetics (NASDAQ:MYGN) reported a 10.5% YoY revenue decline, missing estimates by 8.2%. Gilead Sciences (NASDAQ:GILD) reported $7.80B in revenue, up 10.2% YoY, beating estimates by 6.2%. Moderna (NASDAQ:MRNA) reported $145M in revenue, up 2.1% YoY, surpassing expectations by 35.8%.
3 min readBiogen Inc's (BIIB) stock fell 7% after presenting mixed mid-stage trial results for its Alzheimer's drug diranersen. The study showed positive signals, particularly for the 60 mg dose, but raised questions about dosing and consistency. RBC questioned the replicability of results, while Stifel maintained a 'Buy' rating. BIIB has a 12-month average price target of $224.45, up 7% from the last close.
2 min readThe HSE approved reimbursement for Biogen's Skyclarys after a revised financial offer, following initial cost-effectiveness concerns. Senator Robbie Gallagher called for government reflection on the process and suggested EU-level negotiations for future drug pricing.
1 min readEisai and Biogen announced Japan's approval of LEQEMBI Pen, a subcutaneous formulation of lecanemab for Alzheimer's treatment. The autoinjector allows weekly at-home administration, reducing clinic visits and healthcare resource use. Approval was based on Phase 3 study data, showing similar efficacy and safety to IV administration. Eisai leads development, with both companies co-commercializing.
2 min readUltragenyx (RARE) gained FDA approval for FAYUVI, a treatment for Sanfilippo syndrome Type A, closing at $14.50, up 12.58%. Nuvation Bio (NUVB) expanded IBTROZI's label with new lung cancer data, closing at $6.07, up 5.02%. Bayer (BAYRY) won FDA approval for Kerendia in type 1 diabetes-related CKD, closing at $14.13, up 0.57%. Biogen (BIIB) and Eisai (ESALY.PK) received Japan approval for LEQEMBI Pen, closing at $219.05, up 1.41%. Telix (TLX) got FDA approval for Pixclara, a PET imaging agent fo
3 min readBiogen Inc. (BIIB) reported that EMPAVELI (pegcetacoplan) showed a 75% relative reduction in proteinuria in adolescents with C3G or primary IC-MPGN in a Phase 3 study. The FDA recently expanded EMPAVELI's label to include reducing kidney function loss in patients aged 12 and older. The drug is the only approved treatment for these conditions in adolescents, according to the company.
2 min readA petition for Friedreich’s ataxia treatment omaveloxolone (Skyclarys) reached 100,000 signatures. Biogen withdrew its evidence submission to NICE, halting the appraisal. NICE requires Biogen's participation to recommend the drug. Biogen plans to resubmit evidence when confident of approval.
1 min readEisai (ESAIY) and Biogen (BIIB) announced Japan's approval of Leqembi Pen, a subcutaneous autoinjector for weekly administration. This adds a home-use option to the existing IV treatment given biweekly in hospitals.
1 min readBiogen (BIIB) and Eisai (4523.T) announced Japan's approval of LEQEMBI Pen, a subcutaneous formulation for early Alzheimer's treatment. The pen allows at-home administration, reducing clinic visits. Approval is based on Phase 3 Clarity AD study data. Eisai shares rose 0.44% in Japan, Biogen gained 0.01% in after-hours trading.
2 min read
